Literature DB >> 16529526

Ketamine : from medicine to misuse.

Kim Wolff1, Adam R Winstock.   

Abstract

This review describes the medical, research and recreational uses of ketamine, an anaesthetic derivative of phencyclidine that has dissociative, analgesic and psychedelic properties. Ketamine has a complex mechanism of action that is further complicated by stereoselectivity; however, antagonism of glutamate NDMA receptors is thought to underlie its analgesic, dissociative and neuroprotective effects. While ketamine use in medical and veterinary settings is well documented and has a good safety record, the increase in its unregulated use outside of such controlled environments is a cause for concern. The impact on higher centres in the brain, particularly altered perception of auditory, visual and painful stimuli, results in a general lack of responsive awareness that puts the recreational user at (often unrecognised) risk of personal harm. The perceptual and mood changes observed in those who have consumed ketamine are highly sensitive to age, dose, route of administration, previous experience and setting. At low doses, stimulant effects predominate and the effect of environmental conditions are significant; with higher doses, psychedelic effects predominate and the effect of the environment diminishes. The potential of ketamine as a novel clinical and research tool is matched by its abuse potential outside medical settings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16529526     DOI: 10.2165/00023210-200620030-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  142 in total

1.  The schizophrenia ketamine challenge study debate.

Authors:  W T Carpenter
Journal:  Biol Psychiatry       Date:  1999-10-15       Impact factor: 13.382

2.  Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons.

Authors:  H U Zeilhofer; D Swandulla; G Geisslinger; K Brune
Journal:  Eur J Pharmacol       Date:  1992-03-17       Impact factor: 4.432

3.  Anaesthesia in a disaster zone: a report on the experience of an Australian medical team in Banda Aceh following the 'Boxing Day Tsunami'.

Authors:  B R Paix; R Capps; G Neumeister; T Semple
Journal:  Anaesth Intensive Care       Date:  2005-10       Impact factor: 1.669

4.  Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients.

Authors:  H Ishihara; H Kudo; T Murakawa; A Kudo; S Takahashi; A Matsuki
Journal:  Eur J Anaesthesiol       Date:  1997-01       Impact factor: 4.330

5.  Pharmacological properties of ketamine.

Authors:  J M White; C F Ryan
Journal:  Drug Alcohol Rev       Date:  1996-06

Review 6.  Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity.

Authors:  C W Cotman; D T Monaghan; A H Ganong
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

7.  Long-term dangers of ketamine anaesthesia.

Authors:  B B Collier
Journal:  Br J Anaesth       Date:  1981-05       Impact factor: 9.166

8.  The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.

Authors:  A L Gorman; K J Elliott; C E Inturrisi
Journal:  Neurosci Lett       Date:  1997-02-14       Impact factor: 3.046

Review 9.  [S-(+)-ketamine. Circulatory interactions during total intravenous anesthesia and analgesia-sedation].

Authors:  H A Adams
Journal:  Anaesthesist       Date:  1997-12       Impact factor: 1.041

10.  Evidence of a role for NMDA receptors in pain perception.

Authors:  P Klepstad; A Maurset; E R Moberg; I Oye
Journal:  Eur J Pharmacol       Date:  1990-10-23       Impact factor: 4.432

View more
  45 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  [Addition is also a disease].

Authors:  C Maier
Journal:  Schmerz       Date:  2008-12       Impact factor: 1.107

3.  Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers.

Authors:  Xiaoyin Ke; Yi Ding; Ke Xu; Hongbo He; Minling Zhang; Daping Wang; Xuefeng Deng; Xifan Zhang; Chao Zhou; Yuping Liu; Yuping Ning; Ni Fan
Journal:  Drug Alcohol Depend       Date:  2014-07-11       Impact factor: 4.492

Review 4.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

5.  Neonatal PCP is more potent than ketamine at modifying preweaning behaviors of Sprague-Dawley rats.

Authors:  Sherin Y Boctor; Cheng Wang; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2008-07-30       Impact factor: 4.849

6.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

Review 7.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

Review 8.  [Procedural analgesia : concepts and practice].

Authors:  F Heid; M Gerth; W Roth; M Hessmann; C Werner
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

9.  (S)-(+)-Ketamine hydro-chloride.

Authors:  Patrick Hakey; Wayne Ouellette; Jon Zubieta; Timothy Korter
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-07-16

10.  The participation of NMDA receptors, PKC, and MAPK in the formation of memory following operant conditioning in Lymnaea.

Authors:  David Rosenegger; Ken Lukowiak
Journal:  Mol Brain       Date:  2010-08-31       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.